Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Hematology\Oncology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology\Oncology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Tipping Clonal Hematopoiesis into Transformation
31/12/69 - Acute leukemias of various types are among the most serious blood disorders: leukemia causes severe illness, and the mortality rate is high. A better understanding of the causes of the various forms of leukemia could lead to earlier diagnosis and more effective treatment. The gene ASXL1 is often…

A Phase 3 Trial of l-Glutamine in Sickle Cell Disease
31/12/69 - Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous oxidation?reduction (redox) cofactor in red cells. NAD+ and its reduced form, NADH, play major roles in maintaining redox balance. Sickle red cells have a…

l-Glutamine and the Dawn of Combination Therapy for Sickle Cell Disease
31/12/69 - In 2017, the U.S. Food and Drug Administration approved l-glutamine (USAN, glutamine) for the prevention of acute vaso-occlusive pain events in persons with sickle cell disease who are older than 5 years of age ? only the first drug to be approved for this indication in the 20 years since the…

Parenteral Opioid Shortage ? Treating Pain during the Opioid-Overdose Epidemic
31/12/69 - The opioid-overdose epidemic now causes more than 30,000 deaths per year in the United States. In response to the increasing death toll, many measures have recently been implemented, including reclassification of hydrocodone as a Schedule II opioid and new requirements for physician review of…

Exploiting Viruses to Treat Diseases
31/12/69 - Viruses have evolved to cause both indolent and explosive disease outbreaks, with millions of people infected with the human immunodeficiency virus and hepatitis viruses and with the current outbreaks of Ebola, yellow fever, and Zika viruses in various parts of the world. As a result of intense…

Recurrent Glioblastoma Treated with Recombinant Poliovirus
31/12/69 - Despite aggressive therapy, survival after a diagnosis of World Health Organization (WHO) grade IV malignant glioma is usually less than 20 months, and patients with recurrence usually survive less than 12 months. For decades, research efforts have focused on advancing surgical and radiation…

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
31/12/69 - Adjuvant treatment with tamoxifen for 5 years reduces the recurrence of premenopausal estrogen-receptor?positive breast cancer, with increasing benefits for overall survival during 5 to 15 years of follow-up. Extending the duration of tamoxifen treatment to 10 years further improves outcomes. The…

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
31/12/69 - Breast cancer is the most common cancer in women in the United States and worldwide. Hormone-receptor?positive, axillary node?negative disease accounts for approximately half of all cases of breast cancer in the United States. Adjuvant chemotherapy reduces the risk of recurrence, with effects that…

Endocrine Adjuvant Therapy for Localized Breast Cancer
31/12/69 - Investigators now report in the Journal the updated results of two critical trials of endocrine therapy in early-stage breast cancer ? SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) ? with overlapping groups that permitted a combined analysis. As in many…

TAILORing Adjuvant Systemic Therapy for Breast Cancer
31/12/69 - Five to ten years of adjuvant endocrine therapy provides a substantial benefit in terms of survival outcomes among women with early-stage hormone receptor?positive breast cancer, the most common subtype of breast cancer diagnosed in Western society. Several tools are available to help select women…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins